Fairfax Financial Holdings reports Q1 2026 results today with one of the clearest signals in its positioning data: short sellers have been walking away from this trade.
Short interest is low and getting lower. At just 0.67% of the free float, there is very little bearish conviction in the lending market. More telling is the direction — shorts fell roughly 16% over the past month, with the most notable step-change arriving around April 7, when positions dropped from ~149,000 shares to ~147,000 and continued grinding down toward today's ~139,000. Borrowing this stock is nearly effortless: the cost to borrow runs below 0.7%, and availability in the lending pool is extremely wide. The ORTEX short score of 29 — near the bottom of its recent range — reinforces the picture. This is not a stock with a credible short thesis attracting active capital.
The broader debate among investors is less about short-side pressure and more about whether Fairfax's valuation still offers a compelling margin of safety. The stock trades at a P/E of 11.2 and a price-to-book of 1.24 — undemanding multiples for a company of this quality. Analyst consensus implies roughly 16% upside to the mean price target, though Fairfax has pulled back about 10% year-to-date, leaving the stock at CAD 2,350 after a modest 1.6% recovery over the past month. The EV/EBIT factor score ranks in the 76th percentile, suggesting the market is not yet pricing in full value. The 90-day EPS momentum score at 75 points to steadily improving forward earnings estimates — a quiet tailwind heading into the print.
One genuine point of interest in the ownership data is founder Prem Watsa's 8.97% stake, which has barely moved. A small 2,038-share addition was reported in early March, keeping alignment firmly in place. More broadly, a cluster of director open-market purchases occurred on March 25, with four board members buying at prices around CAD 2,335 — just below today's level — a signal of conviction from those with the best information about what the company was about to report. The only meaningful selling came from subsidiary-level executives in mid-March, which is a more routine activity and carries less informational weight.
The print is therefore less a test of whether the business is broken — the short sellers already answered that — and more a question of whether Q1 investment gains and underwriting margins justify a re-rating toward the analyst consensus price target and back toward the year's highs.
See the live data behind this article on ORTEX.
Open FFH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
